Veys E M
Department of Rheumatology, University Hospital of Gent, Belgium.
Eur J Rheumatol Inflamm. 1994;14(1):23-7.
The effectiveness of etodolac in the treatment of patients with osteoarthritis (OA) and with rheumatoid arthritis (RA) has been well documented in controlled clinical trials. The superiority of etodolac, 300 mg twice daily, over placebo has already been established in short-term trials involving patients with OA. During long-term treatment, significant (p < 0.05) improvement was observed in patients with OA and RA as measured by a variety of efficacy parameters. In comparative studies for OA, etodolac was more effective than conventional indomethacin; naproxen, sustained-release diclofenac, and piroxicam were comparably effective. The newer sustained-release formulation of etodolac is as effective as the conventional etodolac formulation when used to treat patients with OA and those with RA.
依托度酸治疗骨关节炎（OA）和类风湿关节炎（RA）患者的有效性已在对照临床试验中得到充分证明。在涉及OA患者的短期试验中，已证实每日两次服用300 mg依托度酸优于安慰剂。在长期治疗期间，通过各种疗效参数测量发现，OA和RA患者有显著（p < 0.05）改善。在OA的比较研究中，依托度酸比传统的吲哚美辛更有效；萘普生、缓释双氯芬酸和吡罗昔康的疗效相当。当用于治疗OA患者和RA患者时，依托度酸的新型缓释制剂与传统依托度酸制剂效果相同。
